COMMUNIQUÉS West-GlobeNewswire
-
Vericel to Present at the 13th Annual Canaccord Genuity Musculoskeletal Conference
26/02/2018 - 14:00 -
K2M and International Spine Study Group Foundation Collaborate to Advance Data Management Using BACS®
26/02/2018 - 14:00 -
Athenex, Inc. to Report Fourth Quarter and Full Year 2017 Earnings Results on March 26, 2018
26/02/2018 - 14:00 -
Profound Medical to Participate in 2018 BTIG Healthcare Conference
26/02/2018 - 14:00 -
ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial
26/02/2018 - 14:00 -
Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results
26/02/2018 - 14:00 -
Clearside Biomedical Announces Organizational Changes Designed to Support Transition to a Commercial-Stage Company
26/02/2018 - 14:00 -
Radient Technologies Inc. Announces Master Services Agreement with Medical Cannabis Supplier Bonify
26/02/2018 - 14:00 -
Extendicare Announces Agreement to Acquire Lynde Creek Retirement Community
26/02/2018 - 14:00 -
Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial
26/02/2018 - 14:00 -
Hemostemix Signs License Agreement with Aspire Health Science
26/02/2018 - 14:00 -
PotNetwork Holding’s Diamond CBD Books Over $270,000 in Sales at CHAMPS Winter Show at Las Vegas Convention Center
26/02/2018 - 13:37 -
Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Results
26/02/2018 - 13:30 -
Strongbridge Biopharma plc Announces Underwriters’ Partial Exercise of Option to Purchase Additional Shares
26/02/2018 - 13:30 -
SAVE THE DATE: Ninth Annual "Mardi Gras for Autism" Expects 4,000 Attendees at Fullerton Cares Event Raising Awareness for Autism – 4/7/2018
26/02/2018 - 13:30 -
The Joint Corp. to Present at the 30th Annual ROTH Conference
26/02/2018 - 13:05 -
ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
26/02/2018 - 13:01 -
Summit Therapeutics plc : Research Update
26/02/2018 - 13:01 -
Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD
26/02/2018 - 13:00
Pages